# Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation

> **NCT06424236** · PHASE2,PHASE3 · TERMINATED · sponsor: **Washington University School of Medicine** · enrollment: 73 (actual)

## Conditions studied

- Alzheimers Disease
- Dementia
- Alzheimers Disease, Familial

## Interventions

- **DRUG:** Gantenerumab

## Key facts

- **NCT ID:** NCT06424236
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-06-03
- **Primary completion:** 2023-10-06
- **Final completion:** 2023-11-13
- **Target enrollment:** 73 (ACTUAL)
- **Why stopped:** DIAN-TU announced the discontinuation of the DIAN-TU-001 OLE based on the status of the drug program and findings from an interim efficacy analysis and.
- **Last updated:** 2025-02-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06424236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06424236, "Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT06424236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*